Welcome to our dedicated page for TuHURA Biosciences news (Ticker: HURA), a resource for investors and traders seeking the latest updates and insights on TuHURA Biosciences stock.
TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 immuno-oncology company, and the news flow around HURA reflects its focus on overcoming primary and acquired resistance to cancer immunotherapy. This news page aggregates company-issued press releases and other coverage related to TuHURA’s clinical programs, corporate transactions, and financing activities.
Readers can expect updates on TuHURA’s lead innate immune agonist, IFx-2.0, which is being evaluated in a randomized, placebo-controlled Phase 3 registration trial as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel cell carcinoma. News items also cover early-stage and mid-stage clinical work, such as Phase 1b/2a studies in Merkel cell carcinoma of unknown primary origin and plans for Phase 2 development of TBS-2025, the company’s VISTA inhibiting monoclonal antibody in NPM1-mutated relapsed/refractory acute myeloid leukemia.
In addition to clinical milestones, TuHURA’s news includes scientific presentations at major meetings like the American Society of Hematology (ASH) Annual Meeting, where the company has highlighted data on its Delta Opioid Receptor technology and its potential role in reprogramming myeloid-derived suppressor cells and tumor-associated macrophages. Corporate news items detail transactions such as the acquisition of Kineta, Inc., the reverse merger with Kintara Therapeutics, inclusion in the Russell 3000 and Russell 2000 indexes, private placements, at-the-market offering arrangements, and bridge financing.
For investors, researchers, and healthcare professionals following HURA, this page provides a centralized view of TuHURA’s latest announcements on clinical trial progress, pipeline evolution, scientific data releases, and capital markets developments related to its immuno-oncology strategy.
TuHURA Biosciences (Nasdaq: HURA), a Phase 3 registration-stage immune-oncology company, announced its participation in the 2024 Maxim Healthcare Virtual Summit. Dr. James Bianco, President and CEO of TuHURA, was part of the Precision and Immune Oncology panel. The company focuses on developing novel technologies to overcome resistance to cancer immunotherapy. A webcast replay of the panel presentation is available for M-Vest members.
TuHURA Biosciences (NASDAQ:HURA), a Phase 3 registration-stage immune-oncology company, will present at the Virtual Investor "New to the Street" Event on October 30, 2024, at 4:00 PM ET. Dr. Jim Bianco, President and CEO, will provide a corporate overview and business outlook during a live moderated webcast.
Investors can submit questions live during the event, with the company aiming to answer as many as possible. The presentation will be available on TuHURA's website, with a replay accessible for 90 days following the live event.
TuHURA focuses on developing novel technologies to overcome resistance to cancer immunotherapy. This event offers an opportunity for investors to gain insights into the company's progress and future plans in the immune-oncology field.
TuHURA Biosciences has completed its merger with Kintara Therapeutics, creating a Phase 3 registration-stage immune-oncology company. The combined entity will operate as TuHURA Biosciences, Inc. and trade on Nasdaq under the ticker "HURA" starting October 18, 2024. The company's focus is on developing novel technologies to overcome resistance to cancer immunotherapy, with a lead program entering a single Phase 3 accelerated approval registration trial in the first half of 2025 for first-line Merkel Cell carcinoma treatment.
The merger includes a $31 million fully-funded financing, expected to support operations into late 2025. Post-merger, former Kintara equityholders own approximately 2.85% of the combined company, while TuHURA equityholders own about 97.15%. The company's pipeline includes Immune Fx (IFx) Innate Immune Response Agonists and Tumor Microenvironment Modulators, aimed at overcoming primary and acquired resistance to cancer immunotherapies.